{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:25:43Z","timestamp":1764674743053,"version":"3.46.0"},"reference-count":58,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundations of China","doi-asserted-by":"publisher","award":["82073894"],"award-info":[{"award-number":["82073894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"New Medicine Clinical Research Fund","award":["4246Z512"],"award-info":[{"award-number":["4246Z512"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Bloodstream infections (BSIs) caused by MDR Acinetobacter baumannii (MDRAB) have become a serious threat. Tigecycline is one of the last-resort agents for MDRAB, but its monotherapy in BSIs is limited by insufficient serum exposure. Certain combination strategies can enhance anti-infection ability via a synergistic effect, thus achieving acceptable antimicrobial efficacy at a relatively lower concentration. Therefore, this study was conducted to explore tigecycline-based combinations with synergistic activity against MDRAB BSIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four clinically isolated MDRAB strains were investigated. The FIC index (FICI) of tigecycline in combination with clinical common antibiotics was assessed to screen synergistic combination strategies through chequerboard assays. The synergistic effect was then evaluated by an in vitro pharmacokinetics\/pharmacodynamics (PK\/PD) model through simulating human drug serum concentration\u2013time profiles. Finally, a lethal BSI murine model was used to verify the synergistic efficacy of selected combination strategies in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tigecycline combined with meropenem showed the strongest synergistic effect, with an FICI of \u22640.5 for all MDRAB strains, and was consequently selected for subsequent experiments. In the in vitro PK\/PD model, high-dose tigecycline combined with meropenem showed excellent synergistic activity against tigecycline-susceptible but not against non-susceptible MDRAB strains. In a lethal BSI murine model induced by tigecycline-susceptible MDRAB, strong synergistic activity was verified in the high-dose tigecycline\u200a+\u200ameropenem group, with mortality reduced to zero and the bacterial load of blood, liver, lung and kidney significantly decreased (P\u200a&amp;lt;\u200a0.05).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>High-dose tigecycline combined with meropenem displayed an excellent synergistic effect against BSIs caused by tigecycline-susceptible but not non-tigecycline-susceptible MDRAB, therefore providing a promising treatment choice for tigecycline-susceptible MDRAB BSIs in the clinic.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf386","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:09:13Z","timestamp":1759320553000},"page":"3407-3418","source":"Crossref","is-referenced-by-count":0,"title":["The synergistic activity of tigecycline-based combinations against multidrug-resistant\n                    <i>Acinetobacter baumannii<\/i>\n                    -caused bloodstream infections"],"prefix":"10.1093","volume":"80","author":[{"given":"Huan","family":"Zhang","sequence":"first","affiliation":[{"name":"Centre of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Centre, Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beibei","family":"Liang","sequence":"additional","affiliation":[{"name":"Centre of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Centre, Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaoyi","family":"Tan","sequence":"additional","affiliation":[{"name":"Centre of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Centre, Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rui","family":"Wang","sequence":"additional","affiliation":[{"name":"Centre of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Centre, Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6687-9984","authenticated-orcid":false,"given":"Yun","family":"Cai","sequence":"additional","affiliation":[{"name":"Centre of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Centre, Chinese PLA General Hospital , Beijing 100853 ,","place":["China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025120206224827300_dkaf386-B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15620\/cdc:131355","article-title":"Deaths: final data for 2020","volume":"72","author":"Kochanek","year":"2023","journal-title":"Natl Vital Stat Rep"},{"key":"2025120206224827300_dkaf386-B2","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cmi.2019.10.031","article-title":"Burden of bacterial bloodstream infection\u2014a brief update on epidemiology and significance of multidrug-resistant pathogens","volume":"26","author":"Kern","year":"2020","journal-title":"Clin Microbiol Infect"},{"key":"2025120206224827300_dkaf386-B3","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1007\/s00134-020-05950-6","article-title":"Bloodstream infections in critically ill patients: an expert statement","volume":"46","author":"Timsit","year":"2020","journal-title":"Intensive Care Med"},{"key":"2025120206224827300_dkaf386-B4","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2025120206224827300_dkaf386-B5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3389\/fmicb.2019.00539","article-title":"Emerging strategies to combat ESKAPE pathogens in the era of antimicrobial resistance: a review","volume":"10","author":"Mulani","year":"2019","journal-title":"Front Microbiol"},{"key":"2025120206224827300_dkaf386-B6","doi-asserted-by":"publisher","first-page":"e14937","DOI":"10.1097\/MD.0000000000014937","article-title":"Risk factors for acquisition and mortality of multidrug-resistant Acinetobacter baumannii bacteremia: a retrospective study from a Chinese hospital","volume":"98","author":"Zhou","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"2025120206224827300_dkaf386-B7","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jinf.2019.05.017","article-title":"Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: clinical features, therapy and outcome from a multicenter study","volume":"79","author":"Russo","year":"2019","journal-title":"J Infect"},{"key":"2025120206224827300_dkaf386-B8","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/antibiotics10060630","article-title":"Acinetobacter baumannii infections in hospitalized patients, treatment outcomes","volume":"10","author":"Alrahmany","year":"2021","journal-title":"Antibiotics (Basel)"},{"key":"2025120206224827300_dkaf386-B9","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","article-title":"Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis","volume":"18","author":"Tacconelli","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"2025120206224827300_dkaf386-B10","doi-asserted-by":"publisher","first-page":"e0101021","DOI":"10.1128\/Spectrum.01010-21","article-title":"Tigecycline heteroresistance and resistance mechanism in clinical isolates of Acinetobacter baumannii","volume":"9","author":"Jo","year":"2021","journal-title":"Microbiol Spectr"},{"key":"2025120206224827300_dkaf386-B11","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s10096-020-04121-1","article-title":"Tigecycline antibacterial activity, clinical effectiveness, and mechanisms and epidemiology of resistance: narrative review","volume":"41","author":"Yaghoubi","year":"2022","journal-title":"Eur J Clin Microbiol Infect Dis"},{"year":"2023","author":"CHINET","key":"2025120206224827300_dkaf386-B12"},{"key":"2025120206224827300_dkaf386-B13","doi-asserted-by":"publisher","first-page":"3423","DOI":"10.1093\/jac\/dkz337","article-title":"Efficacy and safety of tigecycline in treatment of pneumonia caused by MDR Acinetobacter baumannii: a systematic review and meta-analysis","volume":"74","author":"Mei","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224827300_dkaf386-B14","doi-asserted-by":"publisher","first-page":"3357","DOI":"10.2147\/IDR.S368890","article-title":"Tigecycline suppresses the virulence factors of multidrug-resistant Acinetobacter baumannii allowing human neutrophils to act","volume":"15","author":"Sato","year":"2022","journal-title":"Infect Drug Resist"},{"key":"2025120206224827300_dkaf386-B15","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jgar.2021.04.006","article-title":"Dose optimisation based on pharmacokinetic\/pharmacodynamic target of tigecycline","volume":"25","author":"Leng","year":"2021","journal-title":"J Glob Antimicrob Resist"},{"key":"2025120206224827300_dkaf386-B16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2147\/IDR.S153246","article-title":"A retrospective, comparative analysis of risk factors and outcomes in carbapenem-susceptible and carbapenem-nonsusceptible Klebsiella pneumoniae bloodstream infections: tigecycline significantly increases the mortality","volume":"11","author":"Xiao","year":"2018","journal-title":"Infect Drug Resist"},{"key":"2025120206224827300_dkaf386-B17","doi-asserted-by":"publisher","first-page":"1173906","DOI":"10.3389\/fmicb.2023.1173906","article-title":"Editorial: Antibiotic potentiators against drug-resistant pathogens: discovery, development and clinical applications","volume":"14","author":"Das","year":"2023","journal-title":"Front Microbiol"},{"volume-title":"Performance Standards for Antimicrobial Susceptibility Testing\u2013Thirty-First Edition: M100","year":"2021","author":"CLSI","key":"2025120206224827300_dkaf386-B18"},{"key":"2025120206224827300_dkaf386-B19","doi-asserted-by":"publisher","first-page":"6413982","DOI":"10.1155\/2016\/6413982","article-title":"Efficacy of linezolid and fosfomycin in catheter-related biofilm infection caused by methicillin-resistant Staphylococcus aureus","volume":"2016","author":"Chai","year":"2016","journal-title":"Biomed Res Int"},{"key":"2025120206224827300_dkaf386-B20","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/infdis\/jiu593","article-title":"Host fate is rapidly determined by innate effector-microbial interactions during Acinetobacter baumannii bacteremia","volume":"211","author":"Bruhn","year":"2015","journal-title":"J Infect Dis"},{"key":"2025120206224827300_dkaf386-B21","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1089\/sur.2016.021","article-title":"Current murine models of sepsis","volume":"17","author":"Lewis","year":"2016","journal-title":"Surg Infect (Larchmt)"},{"key":"2025120206224827300_dkaf386-B22","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1093\/jac\/dkaa487","article-title":"Efficacy of dual carbapenem treatment in a murine sepsis model of infection due to carbapenemase-producing Acinetobacter baumannii","volume":"76","author":"Cebrero-Cangueiro","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224827300_dkaf386-B23","doi-asserted-by":"publisher","first-page":"e01989-18","DOI":"10.1128\/AAC.01989-18","article-title":"Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic\/pharmacodynamic model","volume":"63","author":"Bian","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206224827300_dkaf386-B24","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1128\/AAC.49.1.220-229.2005","article-title":"Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects","volume":"49","author":"Muralidharan","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206224827300_dkaf386-B25","doi-asserted-by":"publisher","first-page":"1490372","DOI":"10.3389\/fmicb.2025.1490372","article-title":"Carbapenem treatment options for metallo-beta-lactamase: drug screening and dose optimization of meropenem-based combinations against NDM- or IMP-producing Klebsiella pneumoniae","volume":"16","author":"Che","year":"2025","journal-title":"Front Microbiol"},{"key":"2025120206224827300_dkaf386-B26","first-page":"1283","article-title":"Pharmacodynamics of meropenem in critically ill patients with ventilator-associated pneumonia","volume":"96","author":"Jaruratanasirikul","year":"2013","journal-title":"J Med Assoc Thai"},{"key":"2025120206224827300_dkaf386-B27","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1177\/0091270006291035","article-title":"Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients","volume":"46","author":"Li","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"2025120206224827300_dkaf386-B28","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America guidance on the treatment of AmpC \u03b2-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin Infect Dis"},{"author":"EUCAST","key":"2025120206224827300_dkaf386-B29"},{"key":"2025120206224827300_dkaf386-B30","doi-asserted-by":"publisher","first-page":"ciad428","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025120206224827300_dkaf386-B31","doi-asserted-by":"publisher","first-page":"106487","DOI":"10.1016\/j.ijantimicag.2021.106487","article-title":"Intrapulmonary pharmacokinetics of high doses of tigecycline in patients with ventilator-associated pneumonia","volume":"59","author":"Dimopoulos","year":"2022","journal-title":"Int J Antimicrob Agents"},{"key":"2025120206224827300_dkaf386-B32","doi-asserted-by":"publisher","first-page":"e02056-16","DOI":"10.1128\/AAC.02056-16","article-title":"Efficacy of high-dose meropenem (six grams per day) in treatment of experimental murine pneumonia induced by meropenem-resistant Pseudomonas aeruginosa","volume":"61","author":"Oshima","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2025120206224827300_dkaf386-B33","doi-asserted-by":"publisher","first-page":"e00059-17","DOI":"10.1128\/AAC.00059-17","article-title":"Characterizing the antimicrobial activity of N2,N4-disubstituted quinazoline-2,4-diamines toward multidrug-resistant Acinetobacter baumannii","volume":"61","author":"Fleeman","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"author":"FDA","key":"2025120206224827300_dkaf386-B34"},{"key":"2025120206224827300_dkaf386-B35","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.2147\/IDR.S249352","article-title":"High-dose tigecycline in elderly patients with pneumonia due to multidrug-resistant Acinetobacter baumannii in intensive care unit","volume":"13","author":"Bai","year":"2020","journal-title":"Infect Drug Resist"},{"key":"2025120206224827300_dkaf386-B36","doi-asserted-by":"publisher","first-page":"3837","DOI":"10.2147\/IDR.S322803","article-title":"High-dose versus standard-dose tigecycline treatment of secondary bloodstream infections caused by extensively drug-resistant Acinetobacter baumannii: an observational cohort study","volume":"14","author":"Han","year":"2021","journal-title":"Infect Drug Resist"},{"key":"2025120206224827300_dkaf386-B37","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1007\/s12325-020-01235-y","article-title":"Effectiveness and safety of high dose tigecycline for the treatment of severe infections: a systematic review and meta-analysis","volume":"37","author":"Zha","year":"2020","journal-title":"Adv Ther"},{"key":"2025120206224827300_dkaf386-B38","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5414\/CP204549","article-title":"Acute liver failure caused by high-dose tigecycline: a case report","volume":"62","author":"Zhang","year":"2024","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025120206224827300_dkaf386-B39","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1186\/s12879-022-07258-w","article-title":"A case report of drug-induced liver injury after tigecycline administration: histopathological evidence and a probable causality grading as assessed by the updated RUCAM diagnostic scale","volume":"22","author":"Shi","year":"2022","journal-title":"BMC Infect Dis"},{"key":"2025120206224827300_dkaf386-B40","doi-asserted-by":"publisher","first-page":"e22638","DOI":"10.1097\/MD.0000000000022638","article-title":"Hypofibrinogenemia induced by high-dose tigecycline-case report and review of literature","volume":"99","author":"Fan","year":"2020","journal-title":"Medicine (Baltimore)"},{"key":"2025120206224827300_dkaf386-B41","doi-asserted-by":"publisher","first-page":"116153","DOI":"10.1016\/j.diagmicrobio.2023.116153","article-title":"Pharmacokinetic\/pharmacodynamic evaluation of tigecycline dosing in a hollow fiber infection model against clinical bla-KPC producing Klebsiella pneumoniae isolates","volume":"108","author":"Amann","year":"2024","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2025120206224827300_dkaf386-B42","doi-asserted-by":"publisher","first-page":"926758","DOI":"10.3389\/fcimb.2022.926758","article-title":"Virulence factors of Pseudomonas aeruginosa and antivirulence strategies to combat its drug resistance","volume":"12","author":"Liao","year":"2022","journal-title":"Front Cell Infect Microbiol"},{"key":"2025120206224827300_dkaf386-B43","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2478\/acph-2018-0040","article-title":"Immunomodulatory effects of tigecycline in Balb\/C mice","volume":"68","author":"Elhayek","year":"2018","journal-title":"Acta Pharm"},{"key":"2025120206224827300_dkaf386-B44","doi-asserted-by":"publisher","first-page":"4353","DOI":"10.1111\/bph.14494","article-title":"Immunomodulatory tetracyclines shape the intestinal inflammatory response inducing mucosal healing and resolution","volume":"175","author":"Garrido-Mesa","year":"2018","journal-title":"Br J Pharmacol"},{"key":"2025120206224827300_dkaf386-B45","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1093\/jac\/dkr441","article-title":"Calcium-dependent potentiation of the pro-inflammatory functions of human neutrophils by tigecycline in vitro","volume":"67","author":"Cockeran","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"2025120206224827300_dkaf386-B46","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.3390\/pharmaceutics13122085","article-title":"The development of third-generation tetracycline antibiotics and new perspectives","volume":"13","author":"Rusu","year":"2021","journal-title":"Pharmaceutics"},{"key":"2025120206224827300_dkaf386-B47","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.bbrep.2015.11.003","article-title":"Tetracyclines downregulate the production of LPS-induced cytokines and chemokines in THP-1 cells via ERK, p38, and nuclear factor-\u03baB signaling pathways","volume":"4","author":"Sun","year":"2015","journal-title":"Biochem Biophys Rep"},{"key":"2025120206224827300_dkaf386-B48","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/ni.3798","article-title":"A current view on inflammation","volume":"18","author":"Editorial","year":"2017","journal-title":"Nat Immunol"},{"key":"2025120206224827300_dkaf386-B49","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.tiv.2012.11.015","article-title":"Tigecycline prevents LPS-induced release of pro-inflammatory and apoptotic mediators in neuronal cells","volume":"27","author":"Yagnik","year":"2013","journal-title":"Toxicol In Vitro"},{"key":"2025120206224827300_dkaf386-B50","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13018-025-05467-y","article-title":"Antibacterial evaluation of antibiotic-coated titanium and stainless steel implants in orthopaedic application: a dip-coating approach","volume":"20","author":"Kariksiz","year":"2025","journal-title":"J Orthop Surg Res"},{"key":"2025120206224827300_dkaf386-B51","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3390\/antibiotics11020160","article-title":"Synergistic effect of polyphenol-rich complex of plant and green propolis extracts with antibiotics against respiratory infections causing bacteria","volume":"11","author":"Ramata-Stunda","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025120206224827300_dkaf386-B52","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/antibiotics11020153","article-title":"Assessment of in-vitro synergy of fosfomycin with meropenem, amikacin and tigecycline in whole genome sequenced extended and pan drug resistant Klebsiella pneumoniae: exploring a colistin sparing protocol","volume":"11","author":"Al-Quraini","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"2025120206224827300_dkaf386-B53","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2147\/IDR.S199993","article-title":"Effects of sub-inhibitory concentrations of meropenem and tigecycline on the expression of genes regulating pili, efflux pumps and virulence factors involved in biofilm formation by Acinetobacter baumannii","volume":"12","author":"Navidifar","year":"2019","journal-title":"Infect Drug Resist"},{"key":"2025120206224827300_dkaf386-B54","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1007\/s40265-018-0966-7","article-title":"Meropenem\/vaborbactam: a review in complicated urinary tract infections","volume":"78","author":"Dhillon","year":"2018","journal-title":"Drugs"},{"key":"2025120206224827300_dkaf386-B55","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/jam.14388","article-title":"Quercetin potentiates meropenem activity among pathogenic carbapenem-resistant Pseudomonas aeruginosa and Acinetobacter baumannii","volume":"127","author":"Pal","year":"2019","journal-title":"J Appl Microbiol"},{"key":"2025120206224827300_dkaf386-B56","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1186\/s13054-017-1829-4","article-title":"Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study","volume":"21","author":"Ehmann","year":"2017","journal-title":"Crit Care"},{"key":"2025120206224827300_dkaf386-B57","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1016\/j.xphs.2018.03.023","article-title":"Nonlinear protein binding: not what you think","volume":"107","author":"Deitchman","year":"2018","journal-title":"J Pharm Sci"},{"key":"2025120206224827300_dkaf386-B58","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.xphs.2017.09.006","article-title":"Impact of experimental variables on the protein binding of tigecycline in human plasma as determined by ultrafiltration","volume":"107","author":"Dorn","year":"2018","journal-title":"J Pharm Sci"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3407\/64739777\/dkaf386.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/12\/3407\/64739777\/dkaf386.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T11:22:55Z","timestamp":1764674575000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/12\/3407\/8292775"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":58,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,12,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf386","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"type":"print","value":"0305-7453"},{"type":"electronic","value":"1460-2091"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,10,17]]}}}